【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2013 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2013 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2013 20
2.4.1 McKesson to Acquire Celesio for US$8.49 Billion 20
2.4.2 AstraZeneca to Acquire Remaining 50% Interest in Diabetes Joint Venture from Bristol-Myers Squibb for US$4.3 Billion 22
2.4.3 Shire Completes Acquisition of Majority Interest in ViroPharma for US$2.7 Billion 23
2.4.4 Johnson & Johnson Prices Public Offering of Notes for US$3.5 Billion 24
2.4.5 OncoMed Pharma Enters Into Co-Development Agreement with Celgene 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2013 26
3.1.1 Top M&A Deals in Q4 2013 27
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2012 – Q4 2013 28
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2013 30
3.2.1 Top Initial Public Offerings in Q4 2013 32
3.2.2 Top Secondary Offerings in Q4 2013 32
3.2.3 Top PIPE Deals in Q4 2013 32
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2012-Q4 2013 33
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2012 – Q4 2013 34
3.2.6 Top Venture Financing Deals in Q4 2013 36
3.2.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 37
3.2.8 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 38
3.2.9 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2012 – Q4 2013 39
3.2.10 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2012 – Q4 2013 41
3.2.11 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2012 – Q4 2013 43
3.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2013 44
3.3.1 Top Private Equity Deals in Q4 2013 45
3.3.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2012 – Q4 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2012 – Q4 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2013 53
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2012 – Q4 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2012 – Q4 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2012 – Q4 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 – Q4 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 – Q4 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 – Q4 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 – Q4 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2012 – Q4 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2012 – Q4 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2012 – Q4 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2012 – Q4 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2012 – Q4 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2012 – Q4 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2012 – Q4 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2013 97
7.2.1 Central Nervous System – Deals of the Quarter 99
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2013 101
7.3.1 Infectious Disease – Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2013 104
7.4.1 Immunology – Deals of the Quarter 106
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2013 107
7.5.1 Metabolic Disorders – Deals of the Quarter 109
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2013 111
7.6.1 Cardiovascular – Deals of the Quarter 113
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2013 115
7.7.1 Gastrointestinal – Deals of the Quarter 117
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2013 119
7.8.1 Dermatology – Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2013 122
7.9.1 Respiratory – Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2013 126
7.10.1 Ophthalmology – Deals of the Quarter 128
8 Deal Summary by Geography 129
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2013 129
8.1.1 North America – Deals of the Quarter 131
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2013 134
8.2.1 Europe – Deals of the Quarter 136
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2013 139
8.3.1 Asia-Pacific – Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2013 143
8.4.1 Rest of the World – Deals of the Quarter 145
9 Pharmaceuticals & Healthcare, Global, Top Advisors 146
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 146
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 148
10 Appendix 150
11 Further Information 154
11.1 Methodology 154
11.2 About GlobalData 155
11.3 Disclosure information 156
11.4 Disclaimer 156
【レポート販売概要】
■ タイトル：グローバル製薬業界における事業提携、ライセンシング、投資及びM&A動向：Q4 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013
■ 発行日：2014年2月28日
■ 調査会社：GlobalData
■ 商品コード：GDPH0441QD
■ 調査対象地域：グローバル
- 水晶発振器の世界市場予測（～2022年）The crystal oscillators market is expected to be valued at USD 3.28 Billion by 2022, at a CAGR of 4.4% between 2016 and 2022. The major factors driving the growth of the crystal oscillators market include growing demand for smartphones and connected devices, mainstream adoption of 4G /LTE networks, and rising demand for advanced equipment from the healthcare industry. This report segments the crys …
- 世界の集束イオンビーム装置市場2015The Global Focused Ion Beam Equipment Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Focused Ion Beam Equipment industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Focused Ion Beam Equipment market analysis is provided for the international markets …
- 自動車用サスペンションメンバーの世界市場2019-2023About this market Vehicle makers specifically design high-performance vehicles with advanced features and composite materials to withstand the increased pressure of high-speed driving and offer superior handling. The systems and components used on a high-performance vehicle, especially suspension systems, are designed to offer improved vehicle handling. Hence, the rising demand for high-performanc …
- 世界の艦艇及び水上戦闘艦艇市場（2014-2024）：トレンド、進歩、課題Synopsis This report offers readers insights into technological developments in the Naval Vessels and Surface Combatants market, as well as detailed analysis of the changing preferences of military forces around the world. It also identifies the current trends in the changing industry structure and the challenges faced by industry participants. Summary Technological Developments in the global Nava …
- ハロゲンフリー難燃剤の世界市場：水酸化アルミニウム、有機リン化学品The market size of halogen-free flame retardant was USD 3.36 Billion in 2015 and is projected to register a CAGR of 8.4% between 2016 and 2021 to reach USD 5.38 Billion by 2021. The demand for halogen-free flame retardants will be driven by stringent environmental regulations and fire safety standards for residential and commercial buildings and various consumer electronics. Non-halogenated flame …
- 澱粉誘導体の世界市場：マルトデキストリン、シクロデキストリン、グルコースシロップ、噴霧乾燥澱粉、加水分解物This report analyzes the starch derivatives market, in terms of region, function, type, and application. The starch derivatives market has grown exponentially in the last few years and this trend is projected to continue following the same trend until 2020. The market was valued at USD 45.74 million in 2014 and is projected to grow at a CAGR of 6.1% from 2015 to 2020. In terms of volume, the marke …
- メープルシロップの世界市場2019-2023105 Pages, November 2018 About this market Packaging plays a major role in maple syrup sales in terms of retaining the flavor, taste, product quality, color, texture, and shelf life. Many major companies are collaborating with packaging manufacturers to develop advanced packaging technology for their products to expand their consumer base. The packaging of any product is a brand extension of the p …
- ナノエマルジョンの世界市場：種類別（小分子界面活性剤、タンパク質安定化エマルジョン、多糖類）、用途別（飲料、乳製品、ベーカリー）Emulsion can be described as an emulsion process that consists of at least one immiscible liquid dispersed in another liquid in the form of droplets, whose diameter exceeds 0.1 μm. Earlier emulsions were used in pharmaceutical and animal nutrition industries; however, their use in the food industry has grown noticeably in the past decade. Emulsion in the food is processed to make changes in its or …
- サイクロスポーラ検査の世界市場2015The report presents a detailed analysis of the Cyclospora diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cyclospora definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals &n …
- 世界の滅菌装置市場：製品＆サービス別（機器（熱、低温）、消耗品＆付属品（指標、潤滑剤）、サービス（電子ビーム、ガンマ））、エンドユーザー別（病院＆クリニック、製薬会社）“The global sterilization equipment market size is projected to register a CAGR of 7.0% during the forecast period.” The global sterilization equipment market size is projected to reach USD 12.5 billion by 2024 from USD 8.9 million in 2019, at a CAGR of 7.0%. Growth in this industry is driven by the increasing number of surgeries performed, rising incidences of hospital-acquired infections, growth …
- コグニティブコラボレーションの世界市場予測（～2024年）The cognitive collaboration market is expected to grow at a CAGR of 11.0% during the forecast period due to ease in integration with the already existing environment and increasing need for mobility and collaboration The global cognitive collaboration market size is expected to grow from USD 983 million in 2019 to USD 1,660 million by 2024, at a Compound Annual Growth Rate (CAGR) of 11.0% during t …
- 世界の石炭・消耗燃料市場分析：Analyzing the Global Coal & Consumable Fuels IndustryCoal is a fossil fuel formed in ecosystems where plant remains were saved by water and mud from oxidization and biodegradation. Coal is a readily combustible black or brownish-black rock. It is a sedimentary rock, but the harder forms, such as anthracite coal, can be regarded as metamorphic rocks because of later exposure to elevated temperature and pressure. It is composed primarily of carbon alo …
- 世界のSoftware-Defined Network（SDN）市場展望（～2018）The software-defined networking (SDN) is a burgeoning industry and it exhibits immense potential for growth in coming years. Factors such as rising need for mobility across enterprises, an efficient network of infrastructure and declining cost of network maintenance & operations through SDN deployment are driving the growth of the SDN market. Considering these, the market is slated to grow at a CA …
- 神経内分泌がん(Neuroendocrine Carcinoma)：世界の治験レビュー（2015年上半期版）Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Neuroendocrine Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Carcinoma. It includes an overview of the trial num …
- 3Dプリント複合材料の世界市場2019-2023About this market The increasing adoption of additive manufacturing will trigger the market’s growth in the forthcoming years. 3D printed composites are increasingly being used as raw materials in additive manufacturing. Vendors are also using additive manufacturing for offering products catering in different end-user industries including aerospace, automotive, and medical devices manufacturing in …
